4-acetyl-2-nitrobenzenesulfonyl chloride

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-acetyl-2-nitrobenzenesulfonyl chloride
• 英文别名: 4-acetyl-2-nitrobenzene-1-sulfonyl chloride；4-Acetyl-2-nitrobenzenesulfonyl chloride
• 化学式: C₈H₆ClNO₅S
• 分子量: 263.658
• InChiKey: ABZUJRRJVGBCIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  105
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-acetyl-2-nitrobenzenesulfonyl chloride 、 依托泊苷 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以71%的产率得到4-acetyl-2-nitrobenzenesulfonyl etoposide
  参考文献：
  名称：

  Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells

  摘要：

  Glutathione transferases (GSTs) are often overexpressed in tumors and frequently correlated to bad prognosis and resistance against a number of different anticancer drugs. To selectively target these cells and to overcome this resistance we previously have developed prodrugs that are derivatives of existing anticancer drugs (e.g., doxorubicin) incorporating a sulfonamide moiety. When cleaved by GSTs, the prodrug releases the cytostatic moiety predominantly in GST overexpressing cells, thus sparing normal cells with moderate enzyme levels. By modifying the sulfonamide it is possible to control the rate of drug release and specifically target different GSTs. Here we show that the newly synthesized compounds, 4-acetyl-2-nitro-benzenesulfonyl etoposide (ANS-etoposide) and 4-acetyl-2-nitro-benzenesulfonyl doxorubicin (ANS-DOX), function as prodrugs for GSTA1 and MGST1 overexpressing cell lines. ANS-DOX, in particular, showed a desirable cytotoxic profile by inducing toxicity and DNA damage in a GST-dependent manner compared to control cells. Its moderate conversion of 500 nmol/min/mg, as catalyzed by GSTA1, seems hereby essential since the more reactive 2,4-dinitrobenzenesulfonyl doxorubicin (DNS-DOX) (14000 nmol/min/mg) did not display a preference for GSTA1 overexpressing cells. DNS-DOX, however, effectively killed GSTP1 (20 nmol/min/mg) and MGST1 (450 nmol/min/mg) overexpressing cells as did the less reactive 4-mononitrobenzenesulfonyl doxorubicin (MNS-DOX) in a MGST1-dependent manner (1.5 nmol/min/mg) as shown previously. Furthermore, we show that the mechanism of these prodrugs involves a reduction in GSH levels as well as inhibition of the redox regulatory enzyme thioredoxin reductase 1 (TrxR1) by virtue of their electrophilic sulfonamide moiety. TrxR1 is upregulated in many tumors and associated with resistance to chemotherapy and poor patient prognosis. Additionally, the prodrugs potentially acted as a general shuttle system for DOX, by overcoming resistance mechanisms in cells. Here we propose that GST-dependent prodrugs require a conversion rate "window" in order to selectively target GST overexpressing cells, while limiting their effects on normal cells. Prodrugs are furthermore a suitable system to specifically target GSTs and to overcome various drug resistance mechanisms that apply to the parental drug.

  DOI：

  10.1021/acs.molpharmaceut.6b00140

文献信息

• 벤젠설폰아미드 화합물
  申请人：Ewha University - Industry Collaboration Foundation 이화여자대학교 산학협력단(220040083301) BRN ▼110-82-10456

  公开号：KR102239790B1

  公开（公告）日：2021-04-13

  본 발명은 화학식 1로 표시되는 벤젠설폰아미드 화합물 또는 이것이 바이오틴화된 화합물을 제공한다. 본 발명의 화합물은 시스테인의 산화되지 않은 설프하이드릴기(-SH)와 선택적으로 반응하고, 산화적 변형물과는 반응하지 않는 작용효과를 나타낸다. 따라서, 본 발명의 화합물은 시스테인의 설프하이드릴기를 검출할 수 있다. 또한, 본 발명의 화합물은 각각의 시스테인의 산화반응에 대한 반응성을 측정할 수 있으며, 이에 따라 활성산소 타겟 단백질을 스크리닝할 수 있다.

  本发明提供了一种被表示为化学式1的苯并砜酰胺化合物或其生物素化合物。该发明的化合物与未氧化的半胱氨酸硫羟基（-SH）选择性地反应，并表现出不与氧化修饰物反应的作用效果。因此，该发明的化合物可以检测半胱氨酸的硫羟基。此外，该发明的化合物可以测量每个半胱氨酸的氧化反应的反应性，从而可以筛选活性氧靶蛋白。
• [EN] DEPROTECTION METHOD USING GLUTATHIONE-S-TRANSFERASE AND USE THEREOF<br/>[FR] PROCÉDÉ DE DÉPROTECTION AU MOYEN DE GLUTATHION-S-TRANSFÉRASE ET SON UTILISATION
  申请人：RIKEN

  公开号：WO2012039499A1

  公开（公告）日：2012-03-29

  　本発明のプローブは、グルタチオン－Ｓ－トランスフェラーゼ及び／又はチオール性物質のモニタリング用プローブであって、下記一般式（１）～（３）で示す何れかの保護基が結合している化合物を含む。（一般式（１）～（３）における官能基及び記号の定義は明細書に記載の定義と同じである。）
• Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells
  作者：Marike W. van Gisbergen、Marcus Cebula、Jie Zhang、Astrid Ottosson-Wadlund、Ludwig Dubois、Philippe Lambin、Kenneth D. Tew、Danyelle M. Townsend、Guido R. M. M. Haenen、Marie-José Drittij-Reijnders、Hisao Saneyoshi、Mika Araki、Yuko Shishido、Yoshihiro Ito、Elias S. J. Arnér、Hiroshi Abe、Ralf Morgenstern、Katarina Johansson

  DOI：10.1021/acs.molpharmaceut.6b00140

  日期：2016.6.6

  Glutathione transferases (GSTs) are often overexpressed in tumors and frequently correlated to bad prognosis and resistance against a number of different anticancer drugs. To selectively target these cells and to overcome this resistance we previously have developed prodrugs that are derivatives of existing anticancer drugs (e.g., doxorubicin) incorporating a sulfonamide moiety. When cleaved by GSTs, the prodrug releases the cytostatic moiety predominantly in GST overexpressing cells, thus sparing normal cells with moderate enzyme levels. By modifying the sulfonamide it is possible to control the rate of drug release and specifically target different GSTs. Here we show that the newly synthesized compounds, 4-acetyl-2-nitro-benzenesulfonyl etoposide (ANS-etoposide) and 4-acetyl-2-nitro-benzenesulfonyl doxorubicin (ANS-DOX), function as prodrugs for GSTA1 and MGST1 overexpressing cell lines. ANS-DOX, in particular, showed a desirable cytotoxic profile by inducing toxicity and DNA damage in a GST-dependent manner compared to control cells. Its moderate conversion of 500 nmol/min/mg, as catalyzed by GSTA1, seems hereby essential since the more reactive 2,4-dinitrobenzenesulfonyl doxorubicin (DNS-DOX) (14000 nmol/min/mg) did not display a preference for GSTA1 overexpressing cells. DNS-DOX, however, effectively killed GSTP1 (20 nmol/min/mg) and MGST1 (450 nmol/min/mg) overexpressing cells as did the less reactive 4-mononitrobenzenesulfonyl doxorubicin (MNS-DOX) in a MGST1-dependent manner (1.5 nmol/min/mg) as shown previously. Furthermore, we show that the mechanism of these prodrugs involves a reduction in GSH levels as well as inhibition of the redox regulatory enzyme thioredoxin reductase 1 (TrxR1) by virtue of their electrophilic sulfonamide moiety. TrxR1 is upregulated in many tumors and associated with resistance to chemotherapy and poor patient prognosis. Additionally, the prodrugs potentially acted as a general shuttle system for DOX, by overcoming resistance mechanisms in cells. Here we propose that GST-dependent prodrugs require a conversion rate "window" in order to selectively target GST overexpressing cells, while limiting their effects on normal cells. Prodrugs are furthermore a suitable system to specifically target GSTs and to overcome various drug resistance mechanisms that apply to the parental drug.